Huntington's Disease Research
Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.
Huntington's Disease Research Products Targets
- Adenosine A2A Receptor (11)
- Caspase (9)
- Ubiquitin-activating Enzyme E1 (3)
- Ubiquitin E2 Conjugating Enzyme (3)
- Ubiquitin E3 Ligase (10)
- Deubiquitinating Enzyme (12)
- Hsp90 (10)
- Hsp70 (4)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- Vesicular Monoamine Transporter (4)
- Sir 2-like Family Deacetylase (9)
- Post-Translational Modification (11)
- NMDA Receptor (87)
- Kainate Receptor (22)
- IP3 Receptor (2)
- ERK (6)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Calpain (7)
- Trk Receptor (13)
- Autophagy (44)
- Antioxidant (19)
- Glutamate Transporter (18)
- Dopamine Transporter (20)
- Cathepsin (9)
- Mitochondrial Permeability Transition Pore (3)
- Proteasome (5)
- Histone Deacetylase (19)
- Histone Acetyltransferase (4)
Products for Huntington's Disease Research - Page 39
- Cat.No. Product Name Information/Activity
-
BCC6159
VU 0360223
1274859-33-4
-
BCC7649
VU 1545
890764-63-3
-
BCC7936
VU 29
890764-36-0
-
BCC6969
(2R,4R)-APDC
(2R,4R)-APDC is a selective group II metabotropic glutamate receptors (mGluRs) agonist. (2R,4R)-APDC has anticonvulsant and neuroprotective effects.
-
BCC6609
L-CCG-l
117857-93-9
-
BCC5691
DCG IV
DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1/5R=389/630 μM) and III receptors (IC50: mGlu4/6/7/8R= 22.5/39.6/40.1/32 μM). DCG-IV has anticonvulsive and neuroprotective effects.
-
BCC7614
LY 354740
Eglumegad (LY354740) is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively.
-
BCC7368
LY 379268
Highly selective group II mGlu agonist
-
BCC7623
(±)-LY 395756
852679-66-4
-
BCC6758
MAP4
157381-42-5
